Monitoring immune cell function in patients with severe infections
Monitoring Mitophagy In Myeloid Cells Upon Intensive Care
NA · Centre Hospitalier Universitaire Dijon · NCT05040503
This study is testing how severe infections affect immune cells in ICU patients to see if understanding these changes can help improve treatments for sepsis.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon (other) |
| Drugs / interventions | chemotherapy, prednisone |
| Locations | 1 site (Dijon) |
| Trial ID | NCT05040503 on ClinicalTrials.gov |
What this trial studies
This study investigates the changes in immune cell function, specifically myeloid cells, in patients admitted to the intensive care unit due to septicemia. It aims to understand the phenomenon of myeloid cell immunosuppression, which can worsen infections and complicate treatment. By collecting blood samples at the time of inclusion and 24 hours later, researchers will analyze how energy production in these immune cells is affected during severe infections. The ultimate goal is to adapt existing treatments or develop new strategies to combat sepsis more effectively.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are admitted to the intensive care unit with septicemia.
Not a fit: Patients with known immune deficiencies or those undergoing immunosuppressive treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients suffering from septicemia, potentially reducing mortality and morbidity.
How similar studies have performed: While the specific approach of monitoring myeloid cell function in septic patients is novel, related studies have shown that understanding immune cell behavior can lead to significant advancements in sepsis treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Criteria common to all 4 groups: * Patient (and/or trusted person/health care proxy or relative) or volunteer who provided oral consent after receiving information about the study, or patient included in emergency situation * Age ≥ 18 years Common criteria for patients - Admission to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital Exclusion Criteria: * Person not affiliated to national health insurance * Person subject to a measure of legal protection (curatorship, guardianship) * Person subject to limited judicial protection * Pregnancy or breastfeeding * Known primary or secondary immune deficiency (radiotherapy, chemotherapy, immunosuppressive treatment or systemic corticosteroid therapy in the 3 months preceding inclusion (\> 0.15 mg/kg/d of prednisone equivalent for more than 2 weeks or "bolus" greater than 2mg/kg/d of prednisone equivalent), HIV infection, primary cellular immune deficiency) * Patients hospitalized within 3 months prior to inclusion for sepsis. * Patients receiving therapy known to modulate mitochondrial function, mitochondrial biogenesis or mitophagy (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * Patients with COVID-19
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (RECRUITING)
Study contacts
- Study coordinator: Jean-Pierre QUENOT
- Email: jean-pierre.quenot@chu-dijon.fr
- Phone: 03 80 29 36 85
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Septicemia